Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 11/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 9/20 | 0.44 |
| ▸ | CA2 | P00918 | 9/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PLEC | Q15149 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19449068 | 0.90 | USP2 (0.69) | USP2L3MBTL1CA9POLBMEN1 | |
| SCHEMBL13401323 | 0.83 | USP2 (0.62) | USP2L3MBTL1CA9POLBMEN1 | |
| SCHEMBL10060277 | 0.83 | POLB (0.59) | USP2L3MBTL1CA9POLBMEN1 | |
| SCHEMBL20990646 | 0.82 | USP2 (0.67) | USP2L3MBTL1CA9POLBMEN1 | |
| SCHEMBL10098714 | 0.82 | USP2 (0.76) | USP2L3MBTL1CA9POLBMEN1 | |
| SCHEMBL10177784 | 0.82 | USP2 (0.38) | USP2L3MBTL1CA9POLBMEN1 | |
| SCHEMBL12637546 | 0.81 | USP2 (0.57) | USP2L3MBTL1CA9POLBMEN1 | |
| SCHEMBL14302317 | 0.80 | USP2 (0.48) | USP2L3MBTL1CA9POLBMEN1 | |
| SCHEMBL10014172 | 0.80 | CA9 (0.56) | USP2L3MBTL1CA9POLBMEN1 | |
| SCHEMBL7006557 | 0.79 | ABCB1 (0.50) | USP2L3MBTL1CA9POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319339-A1 | NEUROTENSIN-DERIVED BRANCHED PEPTIDES AND USES THEREOF | BRACCI LUISA (IT) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319339-A1 | NEUROTENSIN-DERIVED BRANCHED PEPTIDES AND USES THEREOF | NTSR1, NTSR2, NGLY1 | USP2 4238/4885L3MBTL1 1348/4885CA9 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.